Lv4
654 积分 2020-08-12 加入
肿瘤相关静脉血栓栓塞症的防治新认识
1天前
已完结
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
10天前
已完结
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
10天前
已完结
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
13天前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
23天前
已完结
A Retrospective Study of Ensartinib-Treated ALK -Positive Locally Advanced or Metastatic NSCLC Patients in China
1个月前
已完结
A Retrospective Study of Ensartinib-Treated ALK -Positive Locally Advanced or Metastatic NSCLC Patients in China
1个月前
已关闭
Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report
1个月前
已关闭
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1个月前
已完结
皖公网安备34019202002308
